Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • Anika Therapeutics' Asset Writedowns and Impairment fell 6365.69% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year decrease of 6392.8%. This contributed to the annual value of $44.7 million for FY2024, which is 2811.06% down from last year.
  • Anika Therapeutics' Asset Writedowns and Impairment amounted to $1.1 million in Q3 2025, which was down 6365.69% from $3.0 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Asset Writedowns and Impairment high stood at $59.6 million for Q4 2023, and its period low was $89000.0 during Q2 2022.
  • In the last 5 years, Anika Therapeutics' Asset Writedowns and Impairment had a median value of $1.2 million in 2021 and averaged $5.6 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first crashed by 8352.55% in 2021, then surged by 355988.94% in 2023.
  • Anika Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $2.9 million in 2021, then tumbled by 44.36% to $1.6 million in 2022, then soared by 3559.89% to $59.6 million in 2023, then tumbled by 68.73% to $18.6 million in 2024, then tumbled by 93.95% to $1.1 million in 2025.
  • Its Asset Writedowns and Impairment stands at $1.1 million for Q3 2025, versus $3.0 million for Q2 2025 and $832000.0 for Q1 2025.